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Hypertension is a leading risk factor of cardiovascular disease and it is becoming increasingly prevalent globally. Correspondingly,
the Chinese government and public health institutions have issued a series of policy documents and guidelines for hypertension.
However, no comprehensive review of such documents has been conducted. Hence, this review aims to provide an up-to-date and
comprehensive assessment of not only the disease burden, but also hypertension management policies and guidelines in China. A
total of 15 epidemiological studies based on national population surveys, 15 Chinese Hypertension Guidelines, and seven policy
documents were identified. We found a larger burden of hypertension in men, while the awareness, treatment, and control rates
have remained low in both sexes. The ranges of hypertension prevalence, awareness, treatment, and control rate among
hypertensive patients were 18.0–44.7%, 23.6–56.2%, 14.2–48.5%, and 4.2–30.1% respectively. Chinese hypertension guidelines
provide evidence-based instructions to healthcare practitioners over hypertension management in which primary healthcare is
increasingly emphasized. Finally, the policy documents set national goals for hypertension management and standardized the
services provided in primary healthcare. The findings highlight the importance of integrating new guidelines into hypertension
management provided by primary healthcare practitioners and the need to evaluate the implementation of guidelines and policies.
Journal of Human Hypertension; https://doi.org/10.1038/s41371-021-00570-z
INTRODUCTION
High blood pressure is one of the leading risk factors for
cardiovascular disease (CVD) and premature deaths worldwide
[1, 2]. In 2010, it was estimated that 1.39 billion adults had
hypertension globally, with higher prevalence in Low- and Middle-
Income Countries (LMICs) [3]. China has also experienced an
increasing prevalence of hypertension over the decades according
to a systematic review published in 2014 [4]. Although the
awareness, treatment and control of hypertension are crucial to
prevent complications, these rates in China remained low
compared with those in developed countries [5]. A few observa-
tional studies over hypertension in China have been conducted
using nationally representative samples [6, 7], but research that
systematically examined their changes over time is limited.
Clinical guidelines provide up to date guidance for preventing
and managing diseases. Periodically, China publishes and updates
national hypertension guidelines, based on international guide-
lines but with substantiated China-specific findings. Since 1999,
five national hypertension guidelines have been developed [8–12].
Although a previous review published in 2015 described the
development of guidelines in China [13], two more national
guidelines and subgroup specific guidelines, focusing on the
elderly and community-based efforts, have been published since
then. Therefore, it is timely to provide a systematic and
comprehensive overview of hypertension guidelines in China.
In response to the rapid increase in hypertension disease
burden, the Chinese government and public health institutions
have increased efforts to develop policies aimed to improve
hypertension management [14]. Noncommunicable disease (NCD)
prevention and control has been increasingly emphasized in
political agendas, especially after China’s healthcare reform in
2009 [15]. In that same year, the Basic Public Health Services
(BPHS) policy was released and set out to provide affordable and
equitable care for diabetes and hypertension, thus potentially
improving the management of hypertension [16]. Several Chinese
policies on hypertension are embedded in national broad health-
related policies, but this review will focus on the hypertension-
specific content in effort to increase our understanding of policy
response in China to address the rising burden of hypertension.
In this state-of-the-art review, we aim to provide an updated
and comprehensive assessment of the following three areas: (1) a
systematic review of the prevalence, awareness, treatment, and
control of hypertension since 2000; (2) national clinical guidelines
on hypertension since 1999; and (3) policies and guidelines in
relation to hypertension management in China.
MATERIALS AND METHODS
Corresponding to the three aims stated above, we describe the
methods used in the sections below.
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Disease burden of hypertension
Search strategy. The search terms used in PubMed were:
“hypertension,” “hypertensive,” “hyperpiesis,” “hyperplasia,” “high
blood pressure,” “elevated blood pressure,” “normotension,”
“raised blood pressure,” OR “prehypertension” in Title, AND
“China,” “Chinese,” “Mainland,” OR “PRC” in Title/Abstract, AND
“prevalence,” OR “aware” AND “treatment” AND “control” in Title/
Abstract. Criteria for inclusion were: [1] The study must have been
published between January 2000 and June 2020; [2] based on a
nationally representative adult population living in mainland
China; [3] study focuses on hypertension; [4] the full text was
written in English. Studies that met the following criteria were
excluded: [1] targeted population was a specific subgroup of
Chinese residents, such as specific occupations, ethnic groups, or
co-morbid diseases, etc; [2] total sample size of less than 1000
individuals; [3] study samples restricted to a single geographic
region in China, such as Northern, Southern, Eastern, Western
China, or fewer than 6 provinces; [4] failure to report data
concerning hypertension prevalence, awareness, treatment, or
control; [5] the study was a systematic review or meta-analysis;
and [6] multiple papers from a same database.
Hypertension was defined as systolic blood pressure over 140
mmHg, diastolic blood pressure over 90mmHg, or taking
antihypertensive medicine [17]. Prevalence was the proportion
of people with hypertension in the whole population. Awareness
was considered as the proportion of those who had been
diagnosed by a doctor to have hypertension or self-reported to
be hypertensive. The proportion of people with hypertension who
were treated with antihypertensive medication was defined as
treatment rate. Control was the proportion of those whose blood
pressure was under control (systolic blood pressure <140 mm Hg
or/and diastolic blood pressure <90mm Hg) [16, 18]. The
hypertension awareness, treatment and control rates were formed
using persons with hypertension as the denominator to increase
comparability across studies, which also applies to studies that
defined controlled hypertension as associated with pharmacolo-
gical treatment [7, 19–22]. One study reported the control rate
among those who were aware of their diagnosis, but we
recalculated it using persons with hypertension as the denomi-
nator [7].
Screening and data extraction. Two reviewers independently
conducted the literature search, screening and data extraction. A
designated third reviewer was consulted to resolve any
incongruities.
Quality and bias assessment. We followed the “NIH Quality
Assessment Tool for Observational Cohort and Cross-Sectional
Studies” for quality assessment of included cohort and cross-
sectional studies [23]. Studies were then ranked as “Good,” “Fair,”
or “Poor” by two reviewers. A third reviewer was involved to
resolve any discrepancies.
Data analysis. The overall hypertension prevalence in the
general population and awareness, treatment, control rates
among participants with hypertension were illustrated in
Fig. 1 Flow chart of literature search and screening of the epidemiological studies on burden of hypertension in China.
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histograms, while sex-specific data were displayed in clustered
histograms. Reference lines of the awareness, treatment and
control rates among people with hypertension in developed
countries in 2000 were extracted from a systematic analysis of 90
countries and shown in the figure, which are 58.8%, 44.5% and
17.9% [24].
Chinese hypertension guidelines
The search for Chinese hypertension guidelines was conducted
using the China National Knowledge Infrastructure digital
database (CNKI). The search terms used in CNKI was “Hyperten-
sion” AND “Guidelines”. The Website of National Center for
Cardiovascular Diseases was also searched to identify released
Table 1. The characteristics of included studies on hypertension in China.
First author Journal Last year of data
collection




Gu, D. Hypertension 2001 15,838 50.6% 35–74 10 Good
Wang, Y. Journal of Human
Hypertension
1997 42,751 44.0% 20–74 11 Fair
Wu, Y. Circulation 2002 14,1892 N/A ≥ 18 31 Fair
Gao, Y. PloS one 2008 46,239 40.1% ≥20 14 Good
Feng, X. L. Bulletin of the World Health
Organization
2012 13,707 47.0% ≥45 28 Good
Wang, J. American Journal of
Hypertension
2010 50,171 50.2% ≥18 13 Good
Feng, Y.J. Biomedical and
Environmental Sciences
2010 76,752 50.3% ≥35 31 Good
Guo, J. Journal of Hypertension 2011 75,528 47.4% ≥18 9 Good
He, M. The Journal of Headache
and Pain
2010 4987 50.8% 18–65 31 Good
Lewington, S. The Lancet 2015 500,233 41.0% 35–74 10 Good
Li, W. Journal of Hypertension 2009 45,108 41.1% 35–70 12 Fair
Li, Y. International Journal of
Cardiology
2014 174,621 42.8% ≥18 31 Good
Lu, J. The Lancet 2017 1,738,886 40.5% 35–75 31 Fair
Wang, Z. Circulation 2015 451,755 47.8% ≥18 31 Fair
Fig. 2 Disease burden of hypertension in China. a Prevalence of hypertension in China. b Awareness, treatment and control rates of
hypertension in China. c Prevalence of hypertension in China by sex. d Awareness, treatment and control rates of hypertension in China
by sex.
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guidelines that were not published in journals. Only documents
released by the Chinese Hypertension League, National Center for
Cardiovascular Diseases, or the Chinese Society of Medicine
aiming at guiding the comprehensive clinical and community
primary hypertension management were included in this review.
All retrieved papers were written in Chinese and examined by
Chinese - English speaking reviewers.
We identified 15 guidelines for hypertension management
published between 1999 and 2020 [8–12, 25–34]. Based on the
selection criteria, this review extracted data from nine major
guidelines that provide comprehensive instructions for general
clinical hypertension management and the community hyperten-
sion management.
Chinese policy documents for hypertension
We searched the State Council website with keyword “NCDs” or
“hypertension” or “diabetes” or “primary healthcare.” A total of 74
documents were found. The inclusion criteria were: (1) it must be a
policy targeting all groups (some policies are for the minorities or
the poor); (2) it must have specific clauses related to hypertension
management. After reviewing the full texts, 27 polices were
included. Seven policies published by the State Council were
presented using a table while the other 20 government
documents were reviewed and summarized.
RESULTS
Disease burden of hypertension
As demonstrated in (Fig. 1), 545 papers were retrieved from
PubMed. The publication titles and abstracts were screened using
the eligibility criteria, and 516 of them were excluded. Thirty-one
publications were selected into full text review. For those studies
derived from the same databases, those that reported the
prevalence, awareness, treatment, and control rate of hyperten-
sion were included. After excluding 16 articles according to the
pre-specified criteria, a total of 15 articles were included in the
review [7, 16, 19–22, 35–43].
The characteristics of the studies included were shown in
Table 1. Sample sizes ranged from 4,987 to 1,738,886 and all
participants were 18 years of age or older. The response rate
varied from 66.4 to 99.65%. The last year of data collection ranged
from 1997 to 2017, and all studies included nine or more
provinces.
Figure 2 shows the disease burden of hypertension according to
the data collection year. The range of hypertension prevalence
among the general population, and the awareness, treatment, and
control rates in people with hypertension were 18.0–44.7%,
23.6–56.2%, 14.2–48.5%, and 4.2–30.1%, respectively [7, 16, 19–
22, 35–43] (Fig. 2a, b, and Supplementary Table 1). Variations in
burden of hypertension among the included studies were due to
many factors such as inconsistencies in age ranges, age-
standardization methods, years of data collection, and sampling
schemes. For instance, on account of different age ranges, in Wu’s
[7] study the prevalence of hypertension was 18.0% with
participants aged 18 years or older, whereas the prevalence in
Lu et. al [40] was 56.1% with participants aged between 35 and 75
years. The awareness and treatment rates increased over time, but
the hypertension control rate remained low. As per sex differences
(Fig. 2c, d), generally a higher prevalence was found in men than
that in women, and women were more likely to have higher rates
of awareness, treatment, and control.
Guidelines
Figure 3 shows the timeline of guidelines publication from 1999 to
2020. Out of 15 guidelines depicted in this timeline, 12 were
published after 2010 and 7 were published within 2017–2019. Six
guidelines did not meet the inclusion criteria. Table 2 summarizes
the changes over time and reflects the trend of hypertension
management [8–12, 25, 28, 32, 34]. These national documents
aimed to provide evidence-based instruction for hypertension
management to health care providers, to translate new research
results into clinical practice, and to promote management and
prevention of hypertension and other chronic diseases in China.
The first Chinese Guidelines for the Management of Hypertension
was published in 1999, introducing a 6-level blood pressure
classification (Supplementary Table 2). This was largely based on
WHO/ISH and the Joint National Committee (JNC) 5 recommenda-
tions [8]. The second guideline was issued in 2005 [9], whereby
modifications included a 5-level blood pressure classification and
removal of “optimal” blood pressures for age groups (Supple-
mentary Table 2). The definition and classification of hypertension
changed again in the 2010 guidelines and control of hypertension
risk factors was addressed for the first time. The risk factors
recognized in the 2010 guidelines include high sodium and low
potassium intake, being overweight or obese, alcohol consump-
tion, long term mental stress, age, family history of hypertension,
physical inactive, smoking, dyslipidemia, and diabetes [10]. In
addition, the 2010 guidelines modified risk factors and risk
stratification for cardiovascular diseases (Supplementary Table 3).
In the 2018 guidelines [11], blood pressure goals for diabetes and
renal diseases were lower than those in previous guidelines. Other
guidelines on specific topics included medications for hyperten-
sion, health education for hypertensive patients, and blood
pressure measurement instructions for healthcare providers.
Community-based hypertension management has been
increasingly emphasized in subsequent editions since the 1999
guideline (Table 2). In 2009, as a response to the national BPHS
policy, the Chinese Hypertension League issued a guideline
focusing on community management for general physicians
working at the community level [28]. The awareness, control
Fig. 3 Publication Timeline of Hypertension Guidelines in China.
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and management rates were promoted as criteria for hyperten-
sion management assessment. In 2014, the second edition of
community-based guidelines was published. The classification of
hypertension patients changed into two levels and an emphasis
on self-management and management in rural areas emerged
[25]. The 2017 community guidelines standardized medical
equipment, healthcare workforce and medication possession in
the community clinics [34]. Following the 2017 version, guidelines
for primary care of hypertension were published in 2019 with
specified blood pressure goals for patients with respective
comorbidities [32]. This guideline standardized the follow-up visit
procedures and emphasized the treatment of acute hypertension.
Policy responses for hypertension prevention and control in
China
Table 3 shows the key messages from seven documents published
by the State Council. The State Council introduced chronic disease
prevention in the 2007 National Disease Control System, and as
one of the leading risk factors for chronic diseases, hypertension
has since gained increased attention [44]. However, it was not
until 2009, when major medical and health system reforms were
initiated, that prevention and treatment of hypertension was
directly mentioned in the plan for Healthcare System Reform [45].
Standards for hypertension management were revised in the
Twelfth Five-Year Plan for Health Service Development [46]. For
example, blood pressure measurements were required for people
aged over 35 years when they were visiting medical institutions.
Most recently, the Thirteenth Five-Year Plan for Hygiene and
Health required that Basic Public Health Services (BPHS) be
delivered to high-risk populations for chronic diseases at the
primary care level, including individual health profiles, physical
examination, regular follow-up visits, and guidance over healthy
lifestyle [47, 48]. Other primary tasks proposed in 2017 were to
further develop an integrated prevention and control system for
NCDs focusing on grassroots healthcare facilities [47].
In total, 20 additional documents regarding the implementation
of BPHS and NCD control are summarized here [49–68]. BPHS was
first released in 2009 [49]. The Opinions on Gradual Equalization to
Promote BPHS specified mandatory public health services,
including providing blood pressure measurements for people
aged over 35 at their first visits to the hospital and management
for hypertensive and diabetic patients [49]. Goals for hypertension
management were gradually increased in later documents. For
example, the target rate of standardized management in
hypertensive patients rose from 35% in 2013 to over 60% in
2017 [51, 53–55]. Meanwhile, the BPHS Service Code began to
promote new patient goals, such as BMI control and blood
pressure control for overweight/obese people with hypertension,
and expanded the service coverage to cover patients and other
high-risk individuals [60, 61]. The Chinese National Health
Commission and the State Council have also issued plans on
NCD control, including the Healthy China 2030 Plan published in
2016 that further stressed the comprehensive prevention and
control of NCDs and set the goal of achieving population-wide
and whole lifecycle health management of NCDs by 2030. Two
documents that focused on special topics addressed other core
pillars of the health system including finance and the utilization of
information technology [67, 68].
DISCUSSION
This review summarized the changes in the burden of hyperten-
sion in China, the development of hypertension management
guidelines, and the policy responses to these changes. A larger
burden of hypertension was observed in men than in women,
while the overall control rate in both sexes remained low. The
Chinese government responded by increasing emphasis on
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diseases in national policies. In addition, since the release of the
first Chinese national hypertension guidelines in 1999, newer
guidelines have been revised according to new scientific and
empirical evidence. In recent years, more guidelines were
published on specific topics and hypertension management at
the primary healthcare level.
The awareness, treatment, and control rates in China have
remained low, although an upward trend has been observed. A
higher prevalence of hypertension was found in males, which is
consistent with previous systematic reviews on hypertension
prevalence in China [4, 5]. This may be explained by the larger
proportion of men with smoking and drinking habits compared to
women [69]. Improvements in awareness, treatment and control
of hypertension might be credited to the enhanced financial
support to hypertension management [5], the dramatic expansion
of health insurance coverage [16, 70], and the implementation of
national hypertension programs that led to the transition from
institutional service to community care [71]. However, the control
rates in China were still far from optimal compared with that in
developed countries [24, 72]. For example, according to the
National Health and Nutrition Examination Survey, the control rate
of hypertension in the United States increased significantly from
31.6% in 1999–2000 to 48.3% in 2009–2010 among hypertensive
patients, with a stable rate of hypertension of around 29.0% [73].
Alternatively, a national survey in China reported a slight increase
in the control rate of hypertension among people with hyperten-
sion from 6.1% in 2002 [7] to 11.2% in 2010 [74].
Chinese hypertension guidelines have been constantly updated
with emerging evidence-based solutions and better access to
antihypertensive medications [9]. The Chinese guidelines are
similar to the guidelines issued by the JNC in the United States,
the European Society of Hypertension and the European Society
of Cardiology (ESH/ESC), and the Canadian Hypertension Educa-
tion Program (CHEP) in many aspects [75]. For example, the
Chinese guidelines published in 2010 and the JNC report similarly
emphasized risk management, such as blood lipid and blood
glucose control, and antiplatelet therapy [10]. In addition, the ESH/
ESC guidelines gradually placed more importance to home blood
pressure monitoring (HBPM) for cardiovascular risk prevention
since 2003 [75]. Likewise, the Chinese Hypertension League issued
a specific Guideline on HBPM in 2019. However, studies show that
physicians would prescribe medications beyond the recom-
mended list of drugs in the guidelines [40, 76]. This indicated
that the guidelines need further promotion among clinical
practitioners to increase their knowledge of and willingness to
adhere to updated hypertension guidelines [40].
Over the years, China has attached more importance on
hypertension management by specifying goals and treatment
plans in its policies. These health polices showed a significant
continuity in terms of hypertension management strategies. For
instance, China has steadily promoted the hierarchical medical
system, national demonstration areas for NCDs management, and
family doctor empanelment to enhance the quality of care. China
has also allocated more funding and provided policy support for
strengthening the grassroots healthcare system with the focus on
NCDs prevention and management [77]. In addition, the strong
intersectoral collaboration seen in recent policies, such as the joint
release of the National Plan on NCD Prevention and Treatment
(2012–2015) by 15 Chinese ministries and commissions, suggests
cohesiveness and shared commitment to stop the growth of NCD
[78]. China’s policies corresponded with the proposals by WHO
that urge governments to create and implement national policies
for NCD risk and burden reduction, generally through increased
access to healthcare and establishment of healthy environments
[79].
The coronavirus disease (COVID-19) started in late 2019 and
quickly swept across the whole world. The unprecedented
pandemic has revealed the inadequacy of health systems and
society at large to tackle rapidly emerging infectious diseases.
Measures to contain COVID-19 such as social distancing and lock-
downs and prioritizing limited medical resources to treat COVID-
19 cases have led to reduced access or lower quality of care for
patients with NCDs. Furthermore, people with NCDs such as
hypertension and related diseases, are at higher risk of contracting
Table 3. Summary of national five-year plans and relevant policy documents for hypertension prevention and control published by the State
Council, China.
Year Title Key points
2007 Outline of the Eleventh Five-year Plan for Health
Service Development
• To establish a national network for the prevention and monitoring of NCDs.
• To strengthen the intervention of risk factors.
• To standardizee and scale up diagnosis and treatment procedures of NCDs.
2009 Plan on Recent Priorities in Carrying out the
Healthcare System Reform (2009-2011)
• Regularly providing guidance for the preventionn and treatment of patients with
hypertension was incorporated into national basic public health services.
2012 The Twelfth Five-Year Plan for National System of
Basic Public Health Services
• To provide free NCDs management services (registration management, health
guidance, regular follow-up and physical examination) for NCDs high-risk groups,
and achieve 40% of hypertension management rate.
2012 Outline of the Twelfth Five-Year Plan for Health
Service Development
• To promote blood pressure measurement of outpatients aged over 35 years in their
first visits at all levels of health institutions.
• Encouraging providing free medications for patients with hypertension and
diabetes in disadvantaged areas.
• To build demonstration areas for comprehensive prevention and control of NCDs.
2016 Thirteenth Five-year Plan for Deepening the
Healthcare System Reform
• To promote the hierarchical medical system and building the treatment-
rehabilitation-long-term-care service chain.
2017 Thirteenth Five-Year Plan for Hygiene and Health • To carry out blood pressure measurement for all first-visit outpatients aged over 35
years old, and gradually provide the risk assessment and intervention guidance for
people at high risk of NCDs.
• The number of patients with hypertension under the health management were
supposed to reach 100 million (target).
• To promote the hierarchical medical system through piloting integrated care of
NCDs, and family doctor empanelment.
2017 The Thirteenth Five-Year Plan to Promote
Equalization of Basic Public Health Services
• To provide registration management, health guidance, regular follow-up and
physical examination services for patients with essential hypertension or type II
diabetes.
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and dying from COVID-19, exacerbating the joint consequences of
NCDs and the pandemic. While low-cost and effective vaccine is
the ultimate weapon against COVID-19, successful development of
vaccines must be coupled with efficient delivery of vaccinations to
vulnerable populations including NCD patients in low-and middle-
income countries to win this battle. Such delivery will require a
well-functioning primary care system and workforce.
STRENGTHS AND LIMITATIONS
A strength of this review is its wide research scope and inclusion
of various literature types. Part one, or the investigation of the
burden of hypertension in China, was based on nationally
representative samples and captures changes in disease burden
overtime. For parts two and three, national guidelines and policy
document series were reviewed in a chronological fashion,
thereby describing the progression and development of the
national responses to hypertension. Not only did we include
specific documents regarding hypertension management, but we
also collected key information from policies with larger scope,
such as the national five-year plans issued by the State Council.
Nevertheless, this study has some limitations. The first part on
disease burden only utilized one database and one language
(English), but this review was systematic and included all national
and regional studies we could find. Our knowledge of Chinese
literature on hypertension indicated that national studies were
published in English not Chinese journals. Second, given the
already broad scope of our review, we did not include information
on risk factors for hypertension or hypertension-related diseases
such as cardiovascular and renal disease. Third, we did not include
evaluation studies on implementation and impacts of the guide-
lines and policies, which are important topics for future research
but beyond the scope of this paper. Lastly, due to the
heterogeneity of the included studies, we were unable to
conclude an estimate of the prevalence of hypertension in China
over time.
CONCLUSION
This review shows the increase of hypertension disease burden in
China, the development of hypertension management guidelines,
and the policy responses to these changes. National clinical
guidelines were developed and updated over time with increasing
specificity within guidelines. Prevention and management of
hypertension has been featured in the National Health Commis-
sion policies and in national plans such as the five-year
development plan and Healthy China 2030. The BPHS policies
initiated in 2009 included hypertension management as one of
the service packages and promoted nation-wide uptake of
hypertension management especially at the primary care level.
Our findings highlighted the importance of integrating new
guidelines into hypertension management provided by primary
healthcare practitioners. Future research is warranted to examine
the implementation of guidelines and policies regarding hyper-
tension management.
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